Building Bridges from Research to Therapy
Lonza’s Pluripotent Stem Cell Innovation Center focuses its efforts in two main areas – technology development and services. In our development programs, we have three priority projects – reprogramming, cell culture system, and differentiation. Each of these technologies is being developed with the needs of the translational researcher and cell therapy client in mind. Each of these technologies is qualified to the highest standard and can be used in our cGMP compliant facilities.
Lonza Bioscience has built up expertise, capacity, and capabilities in pluripotent stem cell research and their application to cGMP manufacturing. Researchers can now access this expertise through our PSC service offering from iPSC generation to process development and differentiation.
We provide the following:
Lonza has the expertise, facilities, and quality systems to support our clients throughout the process. Our clients include:
Figure 1: Lonza services span the full value chain of pluripotent stem cells from tissue acquisition to differentiation.
Specifically, we offer:
Click here for end user restrictions on induced pluripotent stem cell lines manufactured by Lonza.
European Pharmaceutical Review interviews Minh Hong, Sales Manager from Lonza.